Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis

OBJECTIVE: To assess the frequency of cardiovascular and venous thromboembolic events in clinical studies of baricitinib, an oral, selective JAK1 and JAK2 inhibitor approved in more than 50 countries for the treatment of moderately‐to‐severely active rheumatoid arthritis (RA). METHODS: Data were poo...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Arthritis Rheumatol
Hlavní autoři: Taylor, Peter C., Weinblatt, Michael E., Burmester, Gerd R., Rooney, Terence P., Witt, Sarah, Walls, Chad D., Issa, Maher, Salinas, Claudia A., Saifan, Chadi, Zhang, Xin, Cardoso, Anabela, González‐Gay, Miguel A., Takeuchi, Tsutomu
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2019
Témata:
Rheumatoid Arthritis
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6618316/
https://ncbi.nlm.nih.gov/pubmed/30663869
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40841
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky